Coleman, R. L., Brady, M. F., Herzog, T. J., Sabbatini, P., Armstrong, D. K., Walker, J. L., . . . Mannel, R. S. (2017). Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): A multicentre, open-label, randomised, phase 3 trial. Lancet Oncol.
Chicago Style citaatColeman, Robert L., et al. "Bevacizumab and Paclitaxel–carboplatin Chemotherapy and Secondary Cytoreduction in Recurrent, Platinum-sensitive Ovarian Cancer (NRG Oncology/Gynecologic Oncology Group Study GOG-0213): A Multicentre, Open-label, Randomised, Phase 3 Trial." Lancet Oncol 2017.
MLA citatieColeman, Robert L., et al. "Bevacizumab and Paclitaxel–carboplatin Chemotherapy and Secondary Cytoreduction in Recurrent, Platinum-sensitive Ovarian Cancer (NRG Oncology/Gynecologic Oncology Group Study GOG-0213): A Multicentre, Open-label, Randomised, Phase 3 Trial." Lancet Oncol 2017.